278 related articles for article (PubMed ID: 17477810)
1. Bevacizumab in the treatment of colorectal cancer.
Cilley JC; Barfi K; Benson AB; Mulcahy MF
Expert Opin Biol Ther; 2007 May; 7(5):739-49. PubMed ID: 17477810
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in the treatment of colorectal cancer.
Mulcahy MF; Benson AB
Expert Opin Biol Ther; 2005 Jul; 5(7):997-1005. PubMed ID: 16018743
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
Thornton AD; Ravn P; Winslet M; Chester K
Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
[TBL] [Abstract][Full Text] [Related]
4. [New medications; bevacizumab].
Cohen AF; van Bronswijk H
Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in the treatment of metastatic colorectal cancer.
Caprioni F; Fornarini G
Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
[TBL] [Abstract][Full Text] [Related]
6. [Bevacizumab: progress in the treatment of metastatic cancer and hope for patients with proliferative retinopathy].
Antoniak K; Nowak JZ
Postepy Hig Med Dosw (Online); 2007 May; 61():320-30. PubMed ID: 17554235
[TBL] [Abstract][Full Text] [Related]
7. The horizon of antiangiogenic therapy for colorectal cancer.
Olszewski AJ; Grossbard ML; Kozuch PS
Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
[TBL] [Abstract][Full Text] [Related]
8. Vascular biology support for the use of bevacizumab in colorectal cancer.
Doggrell SA
Expert Opin Investig Drugs; 2004 Jun; 13(6):703-5. PubMed ID: 15174956
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy of colorectal cancer: clinical experience with bevacizumab.
Fernando NH; Hurwitz HI
Oncologist; 2004; 9 Suppl 1():11-8. PubMed ID: 15178811
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab.
Ellis LM
Nat Rev Drug Discov; 2005 May; Suppl():S8-9. PubMed ID: 15962523
[TBL] [Abstract][Full Text] [Related]
12. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
13. Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.
Pavlidis ET; Pavlidis TE
World J Gastroenterol; 2013 Aug; 19(31):5051-60. PubMed ID: 23964138
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
Krämer I; Lipp HP
J Clin Pharm Ther; 2007 Feb; 32(1):1-14. PubMed ID: 17286784
[TBL] [Abstract][Full Text] [Related]
15. The role of bevacizumab in colorectal cancer: understanding its benefits and limitations.
Mulder K; Scarfe A; Chua N; Spratlin J
Expert Opin Biol Ther; 2011 Mar; 11(3):405-13. PubMed ID: 21281258
[TBL] [Abstract][Full Text] [Related]
16. Managing patients with metastatic colorectal cancer on bevacizumab.
Lemmens L; Claes V; Uzzell M
Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
[TBL] [Abstract][Full Text] [Related]
17. [Bevacizumab. Progress in cancer therapy by antiangiogenesis].
Krämer I; Lipp HP
Med Monatsschr Pharm; 2006 Jul; 29(7):249-54; quiz 255-6. PubMed ID: 16866078
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenesis agents in colorectal cancer.
Hubbard J; Grothey A
Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
[TBL] [Abstract][Full Text] [Related]
19. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
Collins TS; Hurwitz HI
Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
